Snowden Capital Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Snowden Capital Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-34	Closed	–	–	1033
2021 Q4	$0	Buy	+34	New	+$684	﹤0.01%	2029

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Snowden Capital Advisors's ACAD Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q1 2022, closing a stake of 34 shares.

Snowden Capital Advisors first reported a position in ACAD in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 263 funds tracked by Wall St. Rank hold ACAD as of Q1 2022.

Snowden Capital Advisors reported no remaining Acadia Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 34 Acadia Pharmaceuticals shares in Q1 2022.
Snowden Capital Advisors first reported a position in Acadia Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Acadia Pharmaceuticals position peaked at $0 in Q4 2021.
263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.